Amgen Inc. $AMGN Shares Bought by SS&H Financial Advisors Inc.

SS&H Financial Advisors Inc. increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 28.3% during the third quarter, Holdings Channel reports. The firm owned 15,303 shares of the medical research company’s stock after purchasing an additional 3,375 shares during the period. Amgen makes up 1.3% of SS&H Financial Advisors Inc.’s portfolio, making the stock its 19th largest holding. SS&H Financial Advisors Inc.’s holdings in Amgen were worth $4,319,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Ethic Inc. increased its holdings in shares of Amgen by 3.2% in the third quarter. Ethic Inc. now owns 41,741 shares of the medical research company’s stock valued at $11,779,000 after buying an additional 1,301 shares in the last quarter. KW Wealth Management LLC acquired a new position in shares of Amgen in the 3rd quarter worth $437,000. Warren Street Wealth Advisors LLC raised its position in shares of Amgen by 1.5% during the third quarter. Warren Street Wealth Advisors LLC now owns 5,678 shares of the medical research company’s stock worth $1,602,000 after purchasing an additional 84 shares during the period. Coastwise Capital Group LLC lifted its holdings in shares of Amgen by 1.5% during the third quarter. Coastwise Capital Group LLC now owns 2,833 shares of the medical research company’s stock valued at $799,000 after purchasing an additional 41 shares during the last quarter. Finally, Regatta Capital Group LLC boosted its position in shares of Amgen by 2.4% in the 3rd quarter. Regatta Capital Group LLC now owns 6,690 shares of the medical research company’s stock valued at $1,888,000 after purchasing an additional 159 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Down 0.3%

Amgen stock opened at $332.93 on Monday. Amgen Inc. has a twelve month low of $257.05 and a twelve month high of $346.38. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The firm has a market cap of $179.28 billion, a PE ratio of 25.73, a P/E/G ratio of 3.09 and a beta of 0.45. The firm’s 50 day moving average price is $322.98 and its two-hundred day moving average price is $301.76.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same period in the previous year, the company posted $5.58 EPS. Amgen’s revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s payout ratio is currently 73.57%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Daiwa Capital Markets boosted their price objective on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Morgan Stanley reduced their price target on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Guggenheim lifted their price objective on shares of Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a research report on Thursday, November 6th. Finally, BMO Capital Markets increased their target price on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $332.85.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 in the last three months. 0.69% of the stock is owned by insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.